In this section we report studies of targeted therapies against a broad spectrum of proteins in SCLC (IGF1R, CD13R, mTOR, PLK1, MYC, AuroraKA, AuroraKB, WEE1, BCL-Xl) and summarize the results of these trials in Table S15. This evidence concerns the gene MYC and small cell lung carcinoma.